ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,289.39
0.50%
Dow Jones
39,112.16
-0.76%
Gold vs US Dollar
2,313.12
-0.33%
Brent Oil
84.405
0.26%
Bitcoin
61,635.20
-0.28%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. ACELYRIN Inc (SLRN)

  7. ACELYRIN Inc (SLRN) News

ACELYRIN (SLRN)

ACELYRIN Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SLRN
DateTimeSourceHeadlineSymbolCompany
11/06/202422:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRNACELYRIN Inc
05/06/202412:00GlobeNewswire Inc.ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024NASDAQ:SLRNACELYRIN Inc
29/05/202412:00GlobeNewswire Inc.ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024NASDAQ:SLRNACELYRIN Inc
28/05/202422:20Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:SLRNACELYRIN Inc
25/05/202400:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
25/05/202400:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
25/05/202400:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
18/05/202400:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
18/05/202400:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
18/05/202400:05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
14/05/202421:22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLRNACELYRIN Inc
09/05/202413:14Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SLRNACELYRIN Inc
09/05/202413:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRNACELYRIN Inc
09/05/202413:01GlobeNewswire Inc.ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming MilestonesNASDAQ:SLRNACELYRIN Inc
09/05/202413:00GlobeNewswire Inc.ACELYRIN, INC. Announces Leadership TransitionNASDAQ:SLRNACELYRIN Inc
29/04/202421:05GlobeNewswire Inc.ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024NASDAQ:SLRNACELYRIN Inc
28/03/202420:05GlobeNewswire Inc.ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent HighlightsNASDAQ:SLRNACELYRIN Inc
27/03/202420:01GlobeNewswire Inc.Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 MillionNASDAQ:SLRNACELYRIN Inc
20/03/202411:00GlobeNewswire Inc.ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye DiseaseNASDAQ:SLRNACELYRIN Inc
11/03/202412:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRNACELYRIN Inc
11/03/202412:02GlobeNewswire Inc.ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic ArthritisNASDAQ:SLRNACELYRIN Inc
11/03/202412:00GlobeNewswire Inc.ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for PatientsNASDAQ:SLRNACELYRIN Inc
15/02/202421:05GlobeNewswire Inc.ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate CommunicationsNASDAQ:SLRNACELYRIN Inc
12/01/202410:45PR Newswire (US)SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Acelyrin, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 16, 2024 - (NASDAQ: SLRN)NASDAQ:SLRNACELYRIN Inc
11/01/202423:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
11/01/202423:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
05/01/202410:45PR Newswire (US)SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Acelyrin, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 16, 2024 - (NASDAQ: SLRN)NASDAQ:SLRNACELYRIN Inc
20/12/202321:38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRNACELYRIN Inc
20/12/202321:30GlobeNewswire Inc.ACELYRIN, INC. Appoints Lynn Tetrault to Board of DirectorsNASDAQ:SLRNACELYRIN Inc
18/12/202310:45PR Newswire (US)SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Acelyrin, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 16, 2024 - (NASDAQ: SLRN)NASDAQ:SLRNACELYRIN Inc
 Showing the most relevant articles for your search:NASDAQ:SLRN

Your Recent History

BIT
UB87MS
Unicredit Bank
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved